Journal of Nanobiotechnology (Jul 2022)

Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria

  • Ya Tian,
  • Zhongyuan Zheng,
  • Xi Wang,
  • Shuzhi Liu,
  • Liwei Gu,
  • Jing Mu,
  • Xiaojun Zheng,
  • Yujie Li,
  • Shuo Shen

DOI
https://doi.org/10.1186/s12951-022-01493-8
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 22

Abstract

Read online

Abstract Cerebral malaria (CM) is a life-threatening neurological complication caused by Plasmodium falciparum. About 627,000 patients died of malaria in 2020. Currently, artemisinin and its derivatives are the front-line drugs used for the treatment of cerebral malaria. However, they cannot target the brain, which decreases their effectiveness. Therefore, increasing their ability to target the brain by the nano-delivery system with brain-targeted materials is of great significance for enhancing the effects of antimalarials and reducing CM mortality. This study used glucose transporter 1 (GLUT1) on the blood–brain barrier as a target for a synthesized cholesterol-undecanoic acid–glucose conjugate. The molecular dynamics simulation found that the structural fragment of glucose in the conjugate faced the outside the phospholipid bilayers, which was conducive to the recognition of brain-targeted liposomes by GLUT1. The fluorescence intensity of the brain-targeted liposomes (na-ATS/TMP@lipoBX) in the mouse brain was significantly higher than that of the non-targeted liposomes (na-ATS/TMP@lipo) in vivo (P < 0.001) after intranasal administration. The infection and recurrence rate of the mice receiving na-ATS/TMP@lipoBX treatment were significantly decreased, which had more advantages than those of other administration groups. The analysis of pharmacokinetic data showed that na-ATS/TMP@lipoBX could enter the brain in both systemic circulation and nasal-brain pathway to treat malaria. Taken together, these results in this study provide a new approach to the treatment of cerebral malaria. Graphical Abstract

Keywords